University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Invasive fungal infections are common and often lethal. Despite optimal medical care mortality is 20-30% at six weeks and dramatically rises to 80-100% for drug resistant infection.
These infections occur most commonly in the context of leukemia and bone marrow transplantation and often in young patients with otherwise curable disease.
Orotomides
The researchers, led by Professor William Hope from the University’s Antimicrobial Pharmacodynamics and Therapeutics (APT) Group, have characterised the biochemical and physiologic effects (pharmacodynamics) of F901318, which is the lead compound of the new class of drugs termed the ‘orotomides’.
The ‘orotomides’, discovered by F2G Limited, have a novel mechanism of action which is the specific biochemical interaction through which a drug substance produces its pharmacological effect.
This is the first new class of antifungal agent to be discovered in the last three decades.
The study, which was supported by a research grant by F2G, has been published in mBio.
Clinical studies
APT’s work provides the underpinning evidence for efficacy and dosage justification for the very first patients receiving the new drug. Such information is required by regulatory agencies such as the European Medicines Agency and the Food and Drug Administration before clinical studies can proceed.
Professor Hope, said: “Antifungal resistance represents a major global clinical challenge. This study provides the necessary information to enable F901318 to be developed for clinical use.”
Learn more: Researchers help develop new antifungal drug
The Latest on: Antifungal drug
[google_news title=”” keyword=”antifungal drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- WSU Fungus Researcher Awarded Fulbright to U.K.on May 7, 2024 at 4:47 am
Washington State University bioengineering senior Katy Ayers has received a Fulbright U.S. Student award to further her fungus studies at the University of Exeter in southwest England.Her Fulbright sc ...
- Researchers review current evidence on Candida auris, an emerging multidrug-resistant yeaston May 6, 2024 at 9:56 am
The antifungal resistance of C. auris is a significant public health concern. Mechanistically, this resistance is associated with the alteration of drug targets, activation of cellular stress response ...
- Pediatric Antifungal Utilization: New Drugs, New Trendson May 3, 2024 at 5:01 pm
In response to the increased incidence and high mortality rates, novel antifungal agents have been developed to expand the breadth and effectiveness of treatment options available to clinicians.
- Exeter announces new £3.4 million global funding for solutions to antifungal drug resistanceon May 3, 2024 at 7:50 am
Considering this threat, increasing frequencies of antifungal drug resistance amongst fungi in the natural environment and in patients undergoing hospital treatment means even fewer drugs are ...
- DCA seizes overpriced anti-fungal drug Itracol from Hanumakonda medical shopon May 3, 2024 at 4:42 am
The MRP of the drug on the label was high compared to the ceiling price fixed for the product by the Union Government ...
- Changes in Renal Function After Changes in Antifungal Drug Therapyon April 30, 2024 at 5:00 pm
Secondary objectives included assessing the frequency of changes in antifungal therapy due to infusion-related reactions involving amphotericin B formulations, evaluating mycological cure rates in ...
- Global Ringworm Treatment Industryon April 30, 2024 at 5:42 am
Global Ringworm Treatment Industry is projected to grow from US$ 8.38 Bn in 2023 to US$ 13.91 Bn by 2033, at a CAGR of 5.2% ...
- Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazoleon April 15, 2024 at 5:33 am
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant ...
- Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacyon April 15, 2024 at 2:41 am
Pulmocide has added new nuances to the chorus of evidence for its antifungal, reporting data from the phase 2 OPERA-S study to show the candidate can prevent and eradicate infections without ...
- The threat of fungal infections is growing. Why is it so hard to make new drugs?on February 11, 2024 at 3:06 am
Last summer, the Food and Drug Administration denied an application for a new antifungal drug called olorofim, sending it back to the company with a request for more data. If approved, it would ...
via Google News and Bing News